Sep 23, 2020 / NTS GMT
Matt Pillar - Life Science Connect - Moderator
Welcome to the Business of Biotech. If you've listened to our summer executive sessions, you'll be familiar with Bolt Biotherapeutics. We had a great conversation with Bolt, CEO, Randy Schatzman, about how is keeping the money train rolling despite the disruption of COVID-19.
On today's episode, we're jumping into CMC and patient centricity considerations with two of Dr. Schatzman's brightest stars; doctors Edith Pérez, CMO; and Nathan Ihle, CTO at Bolt. This was a particularly fun and informative episode because it really illustrates the importance of a connection that can be easy to lose that between the technicalities of CMC considerations in preparation for first-in-human studies and the patient first responsibilities that make the Chief Medical Officer role so important for clinical stage biotechs. Let's give it a listen.
In this episode of the Business of Biotech, I am thrilled to sit down with two of Bolt Biotherapeutics' finest new in both cases, stars, Dr. Edith Pérez, who just joined the company as Chief Medical Officer; and Dr.
Bolt Biotherapeutics Inc CMC Considerations For In-Human Studies with Drs. Edith Perez And Nathan Ihle Transcript
Sep 23, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers